Iguratimod improves bleomycin-induced pulmonary inflammation and fibrosis by regulating macrophage polarization through inhibiting the TLR4/NF-κB pathway

Iguratimod improves bleomycin-induced pulmonary inflammation and fibrosis by regulating macrophage polarization through inhibiting the TLR4/NF-κB pathway

IntroductionPulmonary fibrosis (PF) is a fatal pathological subtype of interstitial lung disease, frequently manifests as a pulmonary complication of connective tissue disease. Iguratimod (IGU) is a new class of anti-rheumatic drugs used in the treatment of rheumatoid arthritis (RA). Studies have re...

Full description

Saved in:
Bibliographic Details
Main Authors: Huan Xu, Kaixuan Ma, Ziting Ma, Tianyu Zhuang, Ling Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
interstitial pulmonary fibrosis
inflammation
iguratimod
M1 polarization
TLR4
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1558903/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items